Favorite this paper
How to cite this paper?
Abstract

Cannabis sativa is a plant from the family Cannabaceae which presents in its leaves bioactive compounds with properties that act in diverse pathologies and, as a result, there was an increase of its constituents’ intake, mainly as teas and oils. Tea and cannabis oil contain substances, such as cannabidiol, which are known worldwide for having momentary effects on diseases related to the central nervous system (CNS). In some countries such as the United States, cannabidiol is being evaluated as a dietary supplement for the treatment and prevention of some metabolic syndromes. Cannabidiol is a compound which has anti-inflammatory and antioxidant properties and therefore can act in the treatment of diseases such as diabetes, in addition to the treatment of diseases related to the CNS. This syndrome is directly related to the CNS because the diabetic patient has a characteristic hyperglycemic state which increases the oxidative stress in tissues that are susceptible to secondary complications such as dementia. Both diabetes and dementia affect mainly the elderly people and the treatment with cannabidiol has been studied because of its protective effect on the CNS. However, the results are controversial and it is still necessary to conduct more studies about the properties of the drug in the peripheral system. Therefore, the aim of this study was to evaluate the peripheral effects of the treatment with cannabidiol in diabetic, ischemic and elderly animals. It was used 350-day-old male Wistar streptozotocin-induced diabetic rats. Ischemia was induced by the 4-VO/ ICA surgical model, where the carotid and vertebral arteries were occluded, reducing the flow of cerebral oxygen. Four diabetic groups were established: Sham Diabetic Treated (SDT), Ischemic Diabetic Treated (DIT), Sham Diabetic Vehicle (SDV) and Ischemic Diabetic Vehicle (DIV), the vehicle groups were not treated with cannabidiol. A non-diabetic control group (ND) was also established. The animals were treated (10 mg/kg of body weight per day) for a period of 30 days. The glycemia and body weight were weekly evaluated and, at the end of the treatment, blood samples were collected and organs were removed and weighed. Blood glucose concentrations, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, fructosamine, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were evaluated. The DIT group presented a reduction in hyperglycemia during treatment, but it did not change the body weight values, unlike the group which was also treated with cannabidiol, but was not ischemic (SDT). The DIT group presented even lower values of fructosamine, LDL, HDL, triglycerides and total cholesterol. The treated but not ischemic group (SDT) demonstrated a reduction in the parameters of AST, ALT and in the liver weight. Treatment with cannabidiol showed important results in diabetic and ischemic animals, especially in relation to the hyperglycemic, lipidic and hepatic parameters, which were superior in regard to the untreated animals, and such results may contribute to the treatment of several pathologies with this compound, besides increasing the applications of the leaves from Cannabis sativa in different foods.

Institutions
  • 1 Departamento de Bioquímica / Universidade Estadual de Maringá
  • 2 Departamento de Farmácia / UEM / Universidade Estadual de Maringá
  • 3 Departamento de Farmácia / UEM / Unversidade Estadual de Maringá
  • 4 Departamento de Biotecnologia, Genética e Biologia Celular / Universidade Estadual de Maringá
  • 5 Departamento de Farmacologia / Universidade de São Paulo
  • 6 Departamento de Ciências Fisiológicas / Universidade Estadual de Maringá
Track
  • Health Nutrition
Keywords
Cannabidiol
Diabetes mellitus
cerebral ischemia